Importantly, staining with specific antibodies demonstrated the presence of complement activation products including C3b/iC3b and the terminal complement complex (TCC), confirming that the complement system was activated in and around plaques in AD (Fig. 2). This evidence concerns the gene C3 and Alzheimer disease.